Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/nrrheum.2013.113 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!